Oncology

Post-transplant care has demonstrated that collaboration between hematopoietic cell transplantation (HCT) specialists and local oncologists can safely enhance patient outcomes while reducing caregiver burdens in a recently published research article.

A Phase III clinical trial, ECHELON-3, has demonstrated survival benefits for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) using a combination therapy of brentuximab vedotin (BV), lenalidomide (Len), and rituximab (R).

Significant advancements in tailoring salvage therapy for pediatric patients with relapsed or refractory classic Hodgkin lymphoma (cHL) have been revealed in a recent clinical trial.

A recent study has unveiled a mechanism by which estrogen receptor-positive (ER+) breast cancer cells become more aggressive after spreading to the bone marrow.

A recent Phase I clinical trial has provided promising results for a novel immunotherapy approach to treat early-stage ERBB2-positive breast cancer.

A recent study suggests multi-ancestry polygenic risk scores (PRS) may help refine active surveillance strategies for low- to intermediate-risk prostate cancer.

Selpercatinib, a targeted RET kinase inhibitor, has demonstrated continued efficacy in treating RET fusion-positive non–small cell lung cancer (NSCLC) even after disease progression.

A recent Phase II clinical trial has revealed promising results for men with low-grade prostate cancer on active surveillance (AS).